Diffusion Optics Technology effective for myopia control in children after 42 months
Click Here to Manage Email Alerts
NEW ORLEANS — SightGlass Vision shared data from studies backing up the efficacy of its Diffusion Optics Technology for myopia control during the Association for Research in Vision and Ophthalmology annual meeting.
According to a company press release, in a 6-month extension of the 3-year double-masked, randomized, multisite CYPRESS clinical trial, children wearing Diffusion Optics Technology (DOT) lenses continued to have statistically significant improvements in axial length and cycloplegic spherical equivalent refraction after 42 months of wear. Trial participants were aged 6 to 10 years when the study started.
Another study evaluated axial length progression in the CYPRESS trial’s DOT lens wearers against age-matched emmetropic eye growth data from the Orinda Longitudinal Study of Myopia. Researchers calculated that after 3 years, pathological axial length change in the DOT lens group (0.08 ± 0.06 mm) was 0.23 mm less (73%; P = .003) than in the emmetropic group (0.31 ± 0.05 mm).
Diffusion Optics Technology aims to slow myopia progression in children using thousands of microdots on spectacle lenses that scatter light and reduce contrast on the retina.
At the ARVO meeting, SightGlass Vision also displayed scientific posters highlighting studies that found DOT lenses had no effect on accommodation lag after short-term wear, that the microdots do not limit spatial details and visual performance, and wearers are unlikely to notice substantial drops in contrast.
Calling SightGlass Vision’s work on the studies “extensive and rigorous,” CEO Andrew Sedgwick emphasized in the press release “the depth of our commitment to advancing myopia control, while also building additional confidence in the efficacy, safety and overall performance of Diffusion Optics Technology spectacle lenses.”
Spectacles with SightGlass Vision Diffusion Optics Technology are not available for sale in the U.S.
References:
- Control of myopia using diffusion optics spectacle lenses: Efficacy and safety study (CYPRESS) 42-month results. https://eppro02.ativ.me/web/page.php?page=IntHtml&project=ARVO23&id=3883279. Accessed May 11, 2023.
- Calculated age-independent myopic axial length growth in the CYPRESS clinical trial. https://eppro02.ativ.me/web/page.php?page=IntHtml&project=ARVO23&id=3881836. Accessed May 11, 2023.
- Evaluation of the lag of accommodation with DOT spectacle lenses. https://eppro02.ativ.me/web/page.php?page=IntHtml&project=ARVO23&id=3885763. Accessed May 11, 2023.
- Optical characterization of a Diffusion Optics Technology ophthalmic lens designed for myopia control. https://eppro02.ativ.me/web/page.php?page=IntHtml&project=ARVO23&id=3883849. Accessed May 11, 2023.
- Evaluation of contrast sensitivity with Diffusion Optics Technology lenses. https://eppro02.ativ.me/web/page.php?page=IntHtml&project=ARVO23&id=3881400. Accessed May 11, 2023.
Collapse
Press Release
Read more about
Click Here to Manage Email Alerts